Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CD69 | Q07108 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.52 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.52 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.52 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.52 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.52 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20461147 | 0.86 | BTK (0.49) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20054047 | 0.83 | BTK (0.60) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20461100 | 0.81 | BTK (0.47) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20461246 | 0.81 | BTK (0.62) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL16814060 | 0.81 | BTK (0.54) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20053904 | 0.79 | BTK (0.51) | BTK | |
| SCHEMBL20461040 | 0.79 | BTK (0.48) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL16794020 | 0.79 | BTK (0.81) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20053996 | 0.79 | BTK (0.55) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20461218 | 0.79 | BTK (0.40) | BTKJAK2CYP3A4HRH2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080103-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-04-18 | — | — | EP | disclosed |